Day 4 bone marrow aspirate for prediction of resistance to induction chemotherapy in acute myeloid leukemia

• Published in: Leukemia research Vol. 11; no. 3; pp. 281 - 283
• Main Authors: Archimbaud, Eric, Treille-Ritouet, Danièle, Guyotat, Denis, Viala, Jean-Jacques, Fiere, Denis
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 1987; Elsevier Science
• Subjects: acute myeloid leukemia; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic agents; Biological and medical sciences; Bone Marrow - pathology; Bone marrow aspirate; Chemotherapy; Drug Resistance; Humans; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - pathology; Medical sciences; Middle Aged; Pharmacology. Drug treatments; predictive tests; Prognosis; Time Factors; AML; RD; acute myeloid leukemia; FAB; OF; predictive tests; Bone marrow aspirate; chemotherapy; araC; CR; Therapeutic efficiency; Human; Polychemotherapy; Prognosis; Sensitivity resistance; Biopsy; Bone marrow; Malignant hemopathy; Induction treatment; Acute myelocytic leukemia
• ISSN: 0145-2126; 1873-5835
• DOI: 10.1016/0145-2126(87)90052-X

Bone marrow aspirate was performed on day 4 of a 7-day induction chemotherapy regimen using daunorubicin, cytosine arabinoside and thioguanine in 42 patients with acute myeloid leukemia (AML). The mean percentage of remaining abnormal cells in day 4 bone marrow was significantly higher in patients having resistant disease (RD) than in patients entering complete remission (CR). Except for patients with FAB M3 AML, most patients who had more than 40% abnormal cells in their day 4 bone marrow had RD. In addition, patients entering CR despite having more than 40% abnormal cells remaining in their day 4 bone marrow seemed to have short CR.